CD4+ T cell responses and COVID-19 risk in people with HIV

A T cell correlate tested in people with HIV

Immune correlates analyses ask which measurable immune marker, sampled before an outcome occurs, tracks with later protection. Antibody correlates of COVID-19 risk had already been reported in this cohort; whether T cell responses add independent information, especially in people with HIV (PWH), was the open question. The paper addresses it inside CoVPN 3008 Part A, a prospective cohort of 14,002 participants in sub-Saharan Africa, 83% of them PWH, who received one or two doses of mRNA-1273 depending on baseline SARS-CoV-2 serostatus.

The T cell work was not run on the whole cohort. It used a case-cohort design drawing on stored PBMC from a nested subset, and the correlates analysis was conducted in the per-protocol PBMC Immunogenicity Analysis Set: 39 non-cases and 22 COVID-19 cases, one of whom was in the random immunogenicity subset. That small number of cases is the single most important constraint on how precisely any risk estimate can be read.

Hybrid immunity versus vaccine-only immunity

The cohort split participants by baseline infection status. The Hybrid Group received one dose and had evidence of prior SARS-CoV-2 infection by any of three tests (anti-Nucleocapsid serology, point-of-care anti-Spike serology, or nasal swab NAAT); the Vaccine Group received two doses and tested negative on all three. Prior work in this cohort found COVID-19 risk over one day to six months post-enrollment was 42% lower in Hybrid Group PWH than in Vaccine Group PWH (HR 0.58, 95% CI 0.44–0.77, p < 0.001).

The present T cell analysis focuses its correlate claims on Hybrid Group PWH. That is a scope condition, not a detail: the headline risk gradient is estimated in people who entered vaccination with pre-existing SARS-CoV-2 immunity, and the paper's own conclusion is phrased that way.

What the CD4+ T cell percentage measures

T cell responses were measured by intracellular cytokine staining of PBMC at baseline (M0) and at Peak, defined as four weeks after the last vaccination dose (month 1 for the Hybrid Group). Cells were stimulated with Spike and Nucleocapsid BA.4/5 peptide pools, and the readout is the percentage of CD4+ T cells expressing IFN-γ and/or IL-2, background-subtracted. A secondary readout adds CD154, a marker tied to B cell help, and a functionality score summarizes responses across functional markers.

These are frequencies of responding cells, not antibody titers, and the two cannot be substituted for one another. The paper reports that M0 neutralizing antibody titer against Spike BA.4/5 did not correlate with post-vaccination T cell responses (rho = 0.12, p = 0.37 for Peak CD4+ T cells expressing IFN-γ and/or IL-2), which is why the authors expect the two markers to carry partly separate information.

Risk falls as Peak CD4+ response rises

In Hybrid Group PWH, covariate-adjusted COVID-19 risk at 165 days post-Peak fell as Peak Spike BA.4/5-specific CD4+ T cell response magnitude increased: 15.8% (95% CI 8.8–27.7%) at a 0.1% IFN-γ and/or IL-2 response, 4.7% (2.6–8.2%) at 0.25%, and essentially 0% at 0.3%. The same pattern appeared for the CD154-inclusive readout and for functionality scores, and controlled-risk curves were also downward for the M0 marker, where even low-level responses were associated with reduced risk.

Not every marker behaved this way. Controlled-risk curves for M0 responses to Nucleocapsid BA.4-5 appeared essentially flat, and the authors note that baseline CD4+ T cell responses to Nucleocapsid did not show the same inverse relationship as the Peak Spike responses. The antigen and the time point both matter when reading which measurement is being discussed.

Antibody titer plus T cell score strengthens the model

The paper compared Cox models containing baseline neutralizing antibody titer alone with models containing that titer plus one CD4+ T cell marker. For the pair of M0 nAb-ID50 BA.4/5 and Peak CD4+ functionality score against Spike BA.4/5, the hazard ratios per 1 SD increase were 0.60 (95% CI 0.23–1.57) for the antibody marker and 0.29 (0.12–0.68) for the T cell score, with an overall p < 0.001. The Peak CD4+ functionality score against Spike Ancestral gave a similar picture (HR 0.33, 0.19–0.58; overall p < 0.001).

The authors are careful about what this comparison supports. Goodness-of-fit tests indicated the co-correlate model was stronger than baseline neutralizing antibody titer alone, but not stronger than Peak CD4+ T cell response alone. The antibody hazard ratios in the bivariate models were less precise than the previously reported univariate estimate and did not reach significance, though the point estimates were similar; the paper argues the inverse antibody association is likely real and explains the lost significance by the smaller sample.

Similar Spike responses in people with and without HIV

A separate descriptive comparison looked at whether HIV status changed the T cell picture. At Peak, Spike BA.4/5 response magnitudes and functionality scores were similar between PWH and people without HIV, regardless of baseline SARS-CoV-2 status. At M0, CD4+ T cell responses to Spike, Nucleocapsid, and Envelope/Membrane BA.4/5 antigens were higher in baseline SARS-CoV-2-positive than negative groups.

This matters for how far the correlate can travel. The paper's correlate estimates come from Hybrid Group PWH, and the similar Peak responses in PWH and PWoH are a descriptive observation, not a demonstration that the same risk gradient holds in people without HIV or in the Vaccine Group.

Small case counts and hypothesis-generating subsets

The 22 COVID-19 cases in the correlates set limit precision, and the authors state that no adjustments were made for multiple testing given the limited sample size. The exploratory clustering finding, that a polyfunctional Th1-like CD4+ population was slightly more abundant in non-cases than cases, is described by the authors as hypothesis-generating and proposed for follow-up with finer methods such as scRNA-seq combined with protein-level data.

The practical priority the paper establishes is a comparison, not a threshold for clinical use: in PWH with pre-existing SARS-CoV-2 immunity, post-vaccination Spike-specific CD4+ T cell responses, particularly the Peak functionality score, carry risk information that baseline neutralizing antibody titer alone does not fully capture. The most decision-relevant reading is that the T cell measure and the antibody measure should be considered together in this hybrid-immunity group, while the Vaccine Group and people without HIV remain outside what these estimates directly support.

Sources used in this answer